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Abstract
Background: Hyperlipidemia is a very common condition as it affects millions of people globally. With
approximately 20% of the U.S. population having a total serum cholesterol levels above 240 mg/dL. Red yeast
rice has been used as a natural alternative to statins, Red Yeast Rice (RYR) is a fermented biproduct of rice
where the yeast, monascus purpureus, is grown. The components that makes RYR effective at lowering
cholesterol are monacolin K.
Methods: A search of the literature published in the last twelve years was conducted using Medline, CINAHL,
and ISI Web of Science. The terms researched were: Red Yeast Rice, monascus purpureus, LDL-C, LDL,
hyperlipidemia, statin myalgias. A manual search was performed using references from the articles retrieved
which yielded additional studies to be considered. Studies were eligible for inclusion only if they met all of the
following criteria: statin intolerant adults with statin-induced myalgias resolved after discontinuation of statin
drug. All other studies focusing on other products besides RYR were excluded.
Results: All three studies used for this systematic review demonstrated significant decreases in LDL-C in
comparison to placebo and lifestyle modifications. Study 1 showed a decrease of 43 mg/dL from baseline
LDL at week 12 and a drop of 35 mg/dL at week 24, compared to the placebo group whose LDL cholesterol
decreased 11mg /dL at week 12, and by 15 mg/dL at week 24. Study 2: This 12 week study showed the mean
LDL cholesterol concentration in RYR was 135 compared to 175 mg/dL in the placebo treated group, this was
an overall reduction in 39 points from LDL in the placebo group compared to a 5 point drop in the placebo
group. Study 3 : This 8 week study showed that LDL levels dropped significantly for the Went RYR group
whole LDL decreased by 27.7% compared to placebo which dropped by 1.5 % after the 8 weeks.
Conclusion: Red Yeast Rice has been seen to reduce low density lipoprotein cholesterol by significant
amounts in comparison to a placebo group. With patients requiring multiple lipid lowering medications, and
many failing the generic and inexpensive lovastatin, it is necessary for studies to continue to prove the safety
and efficacy of Red Yeast Rice as a replacement for statin drugs such as pravastatin, simvastatin, atorvastatin or
fluvastatin.
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Abstract   
Background:. Hyperlipidemia is a very common condition as it affects millions of people 
globally. With approximately 20% of the U.S. population having a total serum cholesterol 
levels above 240 mg/dL. Red yeast rice has been used as a natural alternative to statins, Red 
Yeast Rice (RYR) is a fermented biproduct of rice where the yeast, monascus purpureus, is 
grown. The components that makes RYR effective at lowering cholesterol are monacolin K.  
Methods: A search of the literature published in the last twelve years was conducted using 
Medline, CINAHL, and ISI Web of Science.  The terms researched were: Red Yeast Rice, 
monascus purpureus, LDL-C, LDL, hyperlipidemia, statin myalgias. A manual search was 
performed using references from the articles retrieved which yielded additional studies to be 
considered.  Studies were eligible for inclusion only if they met all of the following criteria: 
statin intolerant adults with statin-induced myalgias resolved after discontinuation of statin 
drug. All other studies focusing on other products besides RYR were excluded.  
Results: All three studies used for this systematic review demonstrated significant decreases 
in LDL-C in comparison to placebo and lifestyle modifications. Study 1 showed a decrease 
of 43 mg/dL from baseline LDL at week 12 and a drop of 35 mg/dL at week 24, compared to 
the placebo group whose LDL cholesterol decreased 11mg /dL at week 12, and by 15 mg/dL 
at week 24. Study 2: This 12 week study showed the mean LDL cholesterol concentration in 
RYR was 135 compared to 175 mg/dL in the placebo treated group, this was an overall 
reduction in 39 points from LDL in the placebo group compared to a 5 point drop in the 
placebo group. Study 3 : This 8 week study showed that LDL levels dropped significantly for 
the Went RYR group whole LDL decreased by 27.7% compared to placebo which dropped 
by 1.5 % after the 8 weeks. 
Conclusion: Red Yeast Rice has been seen to reduce low density lipoprotein cholesterol by 
significant amounts in comparison to a placebo group. With patients requiring multiple lipid 
lowering medications, and many failing the generic and inexpensive lovastatin, it is 
necessary for studies to continue to prove the safety and efficacy of Red Yeast Rice as a 
replacement for statin drugs such as pravastatin, simvastatin, atorvastatin or fluvastatin. 
Keywords:  Red yeast rice, Statin intolerant, Hyperlipidemia, LDL-C, SAM.  
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Comparison of Red Yeast Rice With Placebo in lowering LDL-C in Statin-
Intolerant Adult Patients With Hyperlipidemia 
 
BACKGROUND 
Diagnosis of Hyperlipidemia 
 Hyperlipidemia is a very common condition as it affects millions of people globally.  
It is a group of disorders characterized by an excess of lipids in the bloodstream. Lipids are 
transported in the blood as large lipoproteins. Lipoproteins have five major classes all based 
on density, these are chylomicrons, very low density lipoproteins (VLDL), intermediate 
density lipoproteins (IDL), low density lipoproteins (LDL), and high density lipoproteins 
(HDL).  Most triglyceride is transported in chylomicrons or VLDL and most cholesterol is 
carried in LDL and HDL. Hyperlipidemia is a major risk factor for atherosclerosis and 
coronary heart disease (CHD).  Lowering cholesterol levels has been shown to prevent 
coronary artery disease in people with hypercholesteremia, as well as decrease the risk of 
recurrent coronary events and procedures in patients with coronary artery disease (CAD). A 
study published in 2001 has shown evidence of regression of atherosclerotic lesions in 
patients whose lipid levels are lowered.1 
 Hyperlipidemia is a common problem, with approximately 20% of the U.S. 
population having a total serum cholesterol levels above 240 mg/dL.2Diet and exercise are 
the foundation of any treatment and should be emphasized in all patients who have 
hyperlipidemia. Unfortunately, as valuable as diet and exercise can be, they often will not 
bring the patient's LDL-C to goal.3 Statins are usually the medication of choice in patients 
with a high risk of coronary artery disease, coronary artery bypass surgery, or angioplasty.  
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Red Yeast Rice has been used as a natural alternative to statins, because of this; RYR has 
become so popular in western society that demand has affected the purity of the components 
that were traditionally found to lower cholesterol. Toxins have been found in RYR which is 
known to be nephrotoxic. Critinin is a toxin of Menascus Purpureus which has been found in 
larger amounts due to the inappropriate fermenting of RYR. 
 
Recommendations 
In diagnosing for hyperlipidemias, the National Cholesterol Education Program 
(NCEP) Adult Treatment Panel III Guidelines suggests that for primary prevention of 
cardiovascular disease, all adults over the ages of 20-35 should have a fasting lipoprotein 
profile and evaluation of risk factors every 5 years if they are at high risk for cardiovascular 
disease. Lipoprotein analysis should be performed on serum obtained after a 12 hour fast.2 
LDL-C is calculated using the Friedewald formula, by subtracting the level of HDL 
cholesterol from the total level of cholesterol.4 The initial classification is based on an LDL 
cholesterol level which will be the primary target for therapy (see Table 1).   
 
Common Treatment  
The use of statin medication has been shown to decrease low density lipoprotein 
cholesterol (LDL) and therefore lowers negative cardiovascular effects by blocking 3-
hydroxy-3 methylglutaryl Coenzyme A reductase, thus inhibiting the liver’s ability to 
produce LDL cholesterol. This causes an increase in the number of LDL receptors on the 
surface of the liver resulting in more cholesterol being removed from the blood stream.5 
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 There are many statin drugs on the market, most of which have been derived from 
Aspergillus.6 Because of the risk of side effects from statins, which are seen in 10% of 
patients on statin therapy, these drugs are not available over the counter and require a 
prescription.  The most common side effects of these drugs are myalgias, rhabdomyolysis, 
nephrotoxicity, and hepatotoxicity.7  
 
Red Yeast Rice 
 Red Yeast Rice (RYR) is a fermented biproduct of rice where the yeast, Monascus 
purpureus, is grown. Red Yeast Rice contains multiple strains, all of which are being studied 
further for decreasing lipids. In China, RYR has been used for centuries, dating back to the 
Ming Dynasty (1368-1644) for medicinal purposes, food coloring, food preservative, spice 
and general cuisine8 The components that makes RYR effective at lowering cholesterol are 
monacolin K, monacolin J, monacolin M, dihydromevinolin, polyketide monacolins, and 
saturated fatty acids, all of which are known to inhibit cholesterol synthesis. Monacolin K is 
a potent 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, and it is 
also known as mevinolin or lovastatin. Due to the manocolin K content (lovastatin) found in 
some strains of RYR, side effects such as rhabdomyolysis and hepatotoxicity can be seen 
when high or uncontrolled doses of RYR are administered.9 
 
Purpose of the Study 
The question of using Red Yeast Rice in individuals who are intolerant of statin 
therapy is important, as studies have shown that reducing cholesterol ratios decreases 
coronary artery disease (CAD) and cardiovascular compromise.10 With this being stated, 
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there is a continuous debate as to the use of RYR in comparison to statins in decreasing low 
density lipoproteins due to the safety and efficacy of RYR as it is not bound by FDA 
regulations. The issue is one of cost effectiveness since RYR can be obtained at much lower 
prices than some of the non-generic formulations of statins. Since many individuals lack 
insurance coverage and many require other statin medications besides the generic lovastatin, 
it is crucial that medical facilities aid in giving their patients the best medication and 
resources for their money and their health. In this society, if people are able to pay less for a 
medication that can act the same as a prescribed one costing hundreds of dollars, the patient 
will be a compliant one.     
 
Clinical Question 
 Several studies have compared the use of Menascus Purpureus, a strain of RYR, and 
its efficacy with other herbal medications to reduce overall lipid profile, while others have 
compared its efficacy to statins.11 A systematic review of the literature was performed to 
determine whether RYR has the same LDL lowering capabilities as prescription statin 
medication. The main goal is to see if a significant conclusion can be drawn as to whether 
RYR lowered LDL levels to a degree comparable or better than prescription statins, and if 
there is a decrease of intolerable myalgias. 
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METHODS 
Search Strategy 
A systematic review examines original studies which may aid in the contribution to 
medical communities in the understanding of the risks and benefits of the use of Red Yeast 
Rice in decreasing Low Density Lipoprotein Cholesterol, particularly if the previous use of a 
statin produced intolerance in the patient. Only studies published in the last twelve years 
comparing the effects of Red Yeast Rice with placebo in reducing LDL were included. 
Randomized control trials, cohort studies, and case control studies, both prospective and 
retrospective were included. Meta-analyses and Systematic reviews are not addressed.   
 A search of the literature published in the last twelve years was conducted using 
Medline database, CINAHL and the ISI Web of Science (science citation index, current 
contents) from 1998 through 2010 using the Medical Subject Headings of the National 
Library of Medicine (MeSH). The terms researched were: Red Yeast Rice, Monascus 
Purpureus, LDL-C, LDL, Hyperlipidemia, and statin myalgias. A manual search was 
performed using references from the articles retrieved and provided additional studies to be 
considered.   
 
Eligibility Criteria 
Studies were judged suitable for this systematic review and were eligible for inclusion 
only if they met all of the following criteria: statin intolerant adults with statin-induced 
myalgias resolved after discontinuation of statin drug, Red Yeast Rice versus placebo, and 
decreasing LDL-C. Outcomes beyond the use of Red Yeast Rice to lower LDL, such as the 
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use of fish oil or niacin were excluded. Studies that did not include a comparison of RYR to 
placebo were excluded.   
Only results fully reported in journal articles were considered. The methodological 
quality and validity of the selected studies was assessed using the Jadad scale with scores 
ranging from zero to five. Higher scores were given to randomized and/or double blinded 
studies, and if the studies included an appropriate method for randomization. If a study did 
not include methods of randomization but otherwise stated that they were randomized, one 
point was deducted and lower points were given. This method of validity score did not 
eliminate any of the three studies from the review.  
 
RESULTS 
 Sixteen articles were found, after applying the eligibility criteria only three purported 
to compare the role of Red Yeast Rice in lowering LDL in statin intolerant patients. All three 
studies were Randomized placebo controlled trials, and two articles are double blind studies.  
(see Table 2). Most studies focused specifically on the relationship between Red Yeast Rice 
decreasing low density lipoprotein cholesterol in conjunction with lifestyle modification and 
weight loss.  These studies further compare the effects of RYR against placebo and the drop 
in LDL-C.    
 
Study 1 
 Becker et al12 performed a randomized controlled trial of a population consisting of 
adults with dyslipidemia with a history of discontinuation of statin therapy due to myalgias. 
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The baseline patient characteristics found in this study were similar for both treatment vs. 
placebo group. Mean age in both groups were 60.5 and 61.5 respectively (P=0.44), race, 
ethnicity and co morbidities were similar in both groups. Mean weight ranged from 81.0 in 
the treatment group, and 81.9 in placebo group. BMI in treatment was 28.8 versus 29.2 in 
placebo.12  
 
Exclusion criteria for study 
 The randomization process started in September 2006 and March 2007. A total of 174 
patients were screened who had known hypercholesterolemia and had discontinued at least 1 
statin because of myalgias, with resolution of muscle pain when the medication was 
discontinued. A total of 112 patients were ineligible for the study for multiple reasons 
including recent use of statin drug or RYR, history of myositis, rhabdomyolysis, chronic 
pain, and inability to exercise, had a previous myocardial infarction, percutaneous coronary 
intervention, or coronary artery bypass grafting within the last 6 months. Among the 
inclusion criteria, abnormal baseline lab results such as LDL <100 mg/dL, triglycerides 
levels > 400 mg/dL, CPK levels of > 500 U/L, aspartate transferase or alanine transferase 
levels > 1.5 times the upper limit of normal and abnormal thyroid hormone levels. Sixty two 
patients were randomly assigned to receive three 600 mg capsules of RYR or 3 placebo 
capsules twice daily for 24 weeks, totaling 1.8 grams of RYR daily.  Patients were randomly 
assigned to receive these pills. The study included a table of the components which made up 
the formulation of the RYR used, which included 1.02 mg per capsule of Monacolin K 
(lovastatin), 0.0120 of Monacolin JA, 0.0186 of monacolin J, 0.0080 of Monacolin XA, 
0.607 of Monacolin KA.12 
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 Randomization of study 
 Sixty two patients were randomly assigned to blocks of 4 and placed into 4 
categories. These categories included LDL cholesterol level < 150mg/dL, LDL cholesterol 
level > 150mg/dL, body mass index less than 27 kg/m^2, and body mass index of 27 kg/m^2 
or greater. A random assignment list was generated on a computer using the blockrand 
library with a fixed blocked option. 13 The Red Yeast Rice and placebo used were purchased 
and made from the same manufacturer (Sylvan Bioproducts, Kittanning, Pennsylvania). The 
two capsules were identical in size, shape, and color. All of the patients received a 30 day 
supply during their follow up visits. All patients also participated in a 12 week therapeutic 
lifestyle change program.12 
 Results of study 
  Of the 62 participants, the LDL-C in the Red Yeast Rice group decreased by 43 
mg/dL from baseline at week 12 and by 35 mg/dL at week 24, compared to the placebo 
group whose LDL cholesterol decreased by 11mg /dL at week 12, and by 15 mg/dL at week 
24. Low density lipoprotein was significantly lower in the Red Yeast Rice group than the 
placebo group at both weeks.12 
  
 The LDL levels of each group were measured at baseline, 12 weeks, and 24 weeks. 
The RYR group baseline LDL cholesterol level were 163 mg/dL, 120mg/dL at week 12, and 
128 mg/dL at week 24, compared to the placebo group mean LDL cholesterol level of 165 
mg/dL at baseline, 154 mg/dL at week 12, and 149.8 mg/dL at week 24.  At week 24, 9 out 
of 30 patients in the RYR group achieved an LDL <100mg/dL compared to 2 out of 29 in the 
placebo group.12 
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Study 2   
 Heber et al14 demonstrated through a double blind, placebo-controlled, prospective 
randomized 12 week controlled trial comparing Red Yeast Rice, to placebo, showed that 
LDL cholesterol concentrations differed significantly between the red yeast rice group and 
placebo (P<0.001)  Subjects were recruited through newspapers and announcements. Seven 
hundred and twenty eight potential participants were interviewed and screened. A total of 
238 were asked for a visit and fasting blood sample taken for lipid panel. Subjects with LDL 
cholesterol > 161 mg/dL and triglycerides concentrations < 261 mg/dL in the screening 
sample were sent to an outside reference laboratory and entered into the run in phase.  These 
subjects have not been treated previously for hypercholesterolemia, and had to have normal 
liver and renal function tests at baseline to participate in the study.14 
 Exclusion criteria for study 
 Subjects who were taking lipid regulating drugs, hormone replacement therapy, 
immunosuppressive agents, or any drug that affects lipid concentrations, or drugs associated 
with rhadbomyolysis, including erythromycin, and cyclosporine, and those taking insulin, or 
hypoglycemic agents, or known to have an endocrine disease leading to a lipid abnormality 
were  excluded from the study.   A total of 83 subjects, 46 men and 37 women, entered the 
trial.14 
 Randomization of study 
 All 83 subjects were given a screening physical exam and had fasting blood drawings 
on 2 occasions. Blood samples were analyzed in a biomarker laboratory of UCLA center for 
human nutrition. During week 1, placebo capsules were given to both groups to assess 
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compliance with pill taking. Food frequency questionnaires (FFQ) were completed before the 
randomization, and subjects were given an American Heart Association pamphlet instructing 
them in the step I diet (< 30% of energy from fat, and < 10% of energy from saturated fat, 
and < 300 mg cholesterol/d). Subjects were then assigned in a double blind fashion to receive 
capsules containing either rice powder placebo or 2.4 g of Red Yeast Rice daily. Placebo 
capsules resembled the RYR dietary supplement. The treatment group was given 600 mg of 
pulverized fermented RYR in a gelatin capsule by Pharmanex, Inc, Simi Valley CA.14  
 This study was double blind and randomized with 88 white subjects assigned to 2 
treatment groups, focusing on lipid and nutrition.  Lipid data was gathered twice at baseline 
and at weeks 8,9,11, and 12. The first 80 subjects were selected through the use of a random 
permuted block design; the remaining 8 subjects were randomly assigned by staff following 
the same randomized methods used for the first 8 subjects in the group of 80. The subjects 
who participated in the study had the following baseline characteristics, treatment group had 
a total of 42 individuals with an average triglyceride content of 133mg/dL in the treatment 
group compared to 143mg/dL in the placebo group. HDL in the treatment group was 
50mg/dL compared to the HDL levels in the control group of 46mg/dL. LDL levels in the 
treatment group were 174mg/dL compared to LDL levels in the placebo group of 181mg/dL. 
Dietary intake was monitored through a food frequency questionnaire, which was reviewed 
at each visit. Dietary intake forms were used and gathered at each visit to determine the role 
of diet in conjunction with RYR to lower LDL. In the treatment group, baseline intake total 
energy in KJ was 6611, 6443 at week 8, and 5607 in week 12. The control group baseline 
total energy intake was 7448 at baseline, 6987 at week 8, and 6694 at week 12. The 
following were total fat (g/d) measured at baseline, week 8, and week 12 for the treatment 
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group: 55, 54, 44. The total fat for the control group was 66, 60, and 59 respectively. Liver 
function tests were also gathered for both treatment and control group.14 
 Results of study  
 The study demonstrated significant outcomes at week 8 and 12 in the RYR group 
(P<0.001). At the twelfth week, the mean LDL cholesterol concentration in RYR was 135 
mg/dL compared to 175 mg/dL in the placebo treated group. The overall difference in LDL 
points dropped in the RYR group was 39 + 19mg/dL, compared to the placebo group which 
dropped 5+ 22 mg/dL. No side effects were noted for the Red Yeast Rice group. Dietary 
influences did not play a role in decreasing LDL levels as total energy intake and total fat 
consumption between the two groups were similar at baseline and week 8. Blood lipid 
differences between RYR and control group were evident at week 8. With this finding, the 
study concluded that differences in dietary intake cannot account for the decrease in 
cholesterol concentrations. There were no abnormal liver or renal function test results at any 
time for any subject under the study.14 
 
Study 3  
 Lin et al15 conducted a study, demonstrating the effects of 1.2 grams of Monascus 
Purpureus Went Red Yeast Rice compared to placebo in an 8 week randomized, double 
blind, placebo controlled trial.  The participants in each group constituted of male and 
females with equal percentages in both groups, mean age for all participating subjects were 
46 years old, ranging from 23-65years.  More than 80% of the participants had never 
smoked, and a high percentage of these participants had never had alcohol. Both groups had 
comparable BMI ranging from 23.4 kg/m^2 for the placebo group, and 24.3kg/m^2 for the 
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treatment group. Labs were drawn at baseline, and at each follow up visits. The labs drawn 
included LDL, HDL, triglycerides, apolipoproteins A-I and apolipoprotein B. These showed 
no significant differences between both groups during baseline15 
 Randomization 
  Seventy nine patients (39 in treatment and 40 in placebo) were randomly assigned to 
groups, using the permuted-block randomization to categorize the subjects into two different 
groups.  Each subject in each group received either Monascus Purpureus Went rice or 
placebo. The sample size was based on the efficacy outcome, and the standard deviation 
obtained from the change of LDL-C from both groups from baseline to week 8. Assumptions 
were made based on a two sided alpha (type I error) at 0.05 and the beta (type II error) at 
0.10. With these values, an assumption was made that approximately 17 subjects in each 
group was needed to see a difference of 1mmol/L in mean LDL-C.15  
 All individuals in this study participated in a 4 week trial of the American Heart 
Association step I diet. All 79 patients were instructed to continue this diet through the study, 
and were randomly assigned to 8 weeks of treatment with rice powder placebo or monascus 
purpureus Went rice. All patients received instructions from a registered dietician at every 
visit and all were contacted by phone weekly during the study.  Participants were reviewed 
every 4 weeks and blood samples obtained. This study was double blind as the lab staffs 
were blinded to treatment, and received all blood samples labeled with name codes and 
dates.15   
 The treatment group in this study received pulverized monascus purpureus Went rice 
placed in capsules by Y & B Pharmaceuticals Co. Ltd, Taipei, Taiwan. The study also 
demonstrated the composition of monascus purpureus used in the study. The placebo capsule 
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was made from grounded rice with food coloring to mimic the appearance of the RYR.  Both 
RYR and placebo capsules were dispensed by the hospital pharmacy in identical containers 
marked with the participants name codes. All participants were instructed to take one capsule 
of 600 mg RYR or placebo twice daily, 30 minutes after breakfast and dinner for 56 days and 
to return the containers for capsule counts on each clinic visit.15  
 Results of study  
 This study focused on safety and efficacy by drawing labs every 4 weeks which 
included AST, ALT and CPK. After 4 weeks, the RYR group showed a 30.6% decrease in 
LDL compared to the placebo group which was less than a 1.5% drop. At 8 weeks, LDL 
levels for the Went RYR group were 27.7%, placebo was 1.5 %. Not only were LDL levels 
significantly decreased, but total cholesterol was reduced by 21% and triglycerides by 15.8 
%.  The study also focused on the negative side effects that were reported by each 
participant, and 21 of the 37 participants in the placebo group had adverse effects during the 
study. Only 3 of the 21 were non fatal drug related adverse effects.  No fatal side effects were 
noted for the RYR treatment group.15  
 
DISCUSSION 
 Of the studies reviewed, Red Yeast Rice has been seen to reduce low density 
lipoprotein cholesterol by significant amounts in comparison to a placebo group. All three 
studies reviewed emphasized lifestyle modifications in conjunction with Red Yeast Rice and 
the placebo groups. With these findings, it is clear that lifestyle modifications are needed to 
maximize the effects of RYR in its role to decrease LDL-C; however, each treatment group 
demonstrated significant decreases of LDL-C in comparison to their corresponding placebo 
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groups. An assumption can be made that the placebo groups accounted for dietary or lifestyle 
modifications alone. This finding within each study is sufficient in proving that dietary 
modification alone is not enough to lower LDL-C.   
 All three studies provided information regarding the components of the RYR used in 
their studies, and this is important as over the counter RYR found in the US and worldwide 
can have components which are similar if not identical to Lovastatin. Future studies need to 
focus on implementing the main components needed to lower LDL-C and specifications need 
to be made as to what these components are. So far, these have been characterized as 10 
compounds of monacolin K.16 
 Each study included a chart reviewing the components of the Red Yeast Rice that was 
used during the specific study. Comparing all three studies and their treatment components, 
Becker’s study (study 1) demonstrated the highest percentage of monacolin K at 1.02 mg 
/capsule. Heber’s study compared a monacolin K content of 0.2% = 5 mg of RYR. In the 
study, this is equivalent to or comparable to 20-40 mg of lovastatin. Heber continues to 
explain that this minimal amount causes a dramatic and significant drop in cholesterol, 
therefore; it is not only the menacolin K content found, but rather, a combination of actions 
of multiple monacolins, with other substances found within the Red Yeast Rice.17 
 
CONCLUSION 
 The question of whether Red yeast Rice is a suitable alternative to lower LDL-C in 
statin intolerant adults is an important and practical one for all health care providers. The 
current standard of care entails treating each patient with the best medical knowledge and 
with suitable resources where the patient will be able to afford medications. With patients 
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requiring multiple lipid lowering medications, and some failing the generic and inexpensive 
lovastatin, it is necessary for studies to continue to prove the safety and efficacy of Red Yeast 
Rice as a replacement for statin drugs such as pravastatin, simvastatin, atorvastatin or 
fluvastatin.  It is in the best interest of the public to recommend a drug such RYR under the 
supervision of a physician who can routinely monitor liver enzymes and creatinine kinase 
levels to prevent myalgias and rhabdomyolysis.   
 Based on the results demonstrated by all studies reviewed in this paper, and the 
positive effects seen with the use of RYR for lowering LDL-C, further and larger sample size 
studies are clearly warranted. This topic is of great interest to our health care system as 
multiple co-morbidities are starting to arise in infancy, and young adults that are now 
warranting the use of statins in younger generations. Statin induced myalgias are a serious 
clinical problem as more clinicians will continue to administer statins as first line treatment 
to prevent cardiovascular disease in patients with hyperlipidemia. Studies should focus on 
specifying the concentrations of RYR needed to adequately and safely decrease cholesterol 
without compromising the cholesterol lowering effects of RYR, as this is still a confusing 
factor for many individuals. Furthermore, more RTC need to be conducted that compare 
RYR to statins directly. For instance, one recent randomized, double blind trial study18 has 
demonstrated the comparison of pravastatin versus Red Yeast Rice in a population with statin 
induced myalgias, The results showed that RYR was as well tolerated as pravastatin in 
patients with a history of SAM (statin associated myalgias), both also showed similar levels 
of LDL-C reduction, and similar reduction rates of recurrent myalgias.   
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Tables 
Table 1: Classification of LDL-C 
Initial 
classification  
 Total cholesterol 
and HDL-C  
 
Optimal LDL-C  < 100 mg/dL. Desirable total 
cholesterol  
<200 mg/dL 
Near or above 
optimal LDL-C 
100- 129 mg/dL Borderline high 
blood cholesterol  
200-239 mg/dL 
Borderline high –
LDL-C  
130-159 mg/dL High blood 
cholesterol  
>240 mg/dL  
Very high LDL –C  >190 mg/dL Low HDL – C  <40 mg/dL –
counted as a risk 
factor  
  High HDL –C  >60  negative risk 
factor  
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Table 2. Summary Matrix of Review articles  
 
study Yr.  
published 
Patients/  
Population 
Interventio
n 
Comparis
on 
Outcome(s) Study type Validit
y 
(Jadad 
score) 
Becker et 
al12 
2009 Patients with 
dyslipidemia 
intolerant to 
statins due to 
myalgias 
Red Yeast 
Rice  
Placebo Lowering of 
LDL 
cholesterol   
Randomize
d controlled 
trial  
4 
Heber et al14  1999 American 
population 
consuming a 
similar diet to 
the American 
Heart 
Association.  
Red Yeast 
Rice, diet 
providing 
30% of 
energy from 
fat, <10% 
sat fat, <300 
mg 
cholesterol 
daily.  
Placebo  Total 
cholesterol, 
triacylglycerol, 
HDL,LDL 
cholesterol.  
 
Double 
blind, 
placebo 
controlled 
porspective
ly 
randomized 
12 week 
controlled 
trial  
 4 
Lin et al15  2005 Adult patients 
with 
dyslipidemia.  
Monascus 
Purpureus 
Went rice   
Placebo  Lipid lowering 
effects on 
serum lipids 
LDL-C, total 
cholesterol, 
triglycerides 
and 
apolipoproteins
B, HDL  
Randomize
d double 
blind, 
placebo 
controlled 
study 
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